LOGIN  |  REGISTER
Chimerix

Life Science Company Leadership Changes

ProQR Therapeutics Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

April 23
Last Trade: 2.02 0.02 1.00

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual General Meeting (AGM) of Shareholders will take place on Wednesday, May 22, 2024 at 1630 CET (10:30am EDT) at the offices of Allen & Overy LLP,...Read more


Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

April 23
Last Trade: 1.22 0.00 0.00

CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership...Read more


CEL-SCI Appoints Mario Gobbo to Board of Directors

April 23
Last Trade: 1.47 -0.04 -2.65

VIENNA, Va. / Apr 23, 2024 / Business Wire / CEL-SCI Corporation (NYSE American: CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory services. He has served as an officer or director for a number of...Read more


Evotec appoints Dr Christian Wojczewski as Chief Executive Officer

April 23
Last Trade: 7.65 0.29 3.94

HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that began in January. Dr Mario Polywka, who has led Evotec as Interim CEO since 03...Read more


KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors

April 22
Last Trade: 11.21 -0.23 -2.01

CAMBRIDGE, Mass. & SALISBURY, England / Apr 22, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that William C. Fairey has been appointed to the Company’s Board of Directors, effective immediately. Mr. Fairey was most recently the Chief Commercial Officer...Read more


Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer

April 22
Last Trade: 0.63 0.0077 1.24

FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer (“CFO”), effective as of the day after the filing of the Company’s Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. With a wealth of experience and a proven...Read more


Nutex Health Announces Changes To Its Board Of Directors

April 22
Last Trade: 0.67 -0.02 -3.29

HOUSTON, April 22, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 9 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Scott J. Saunders, and Kelvin Spears, MD, to its Board of Directors.  They replace John Waters,...Read more


ArriVent BioPharma Appoints Kristine Peterson to its Board of Directors

April 22
Last Trade: 15.77 0.00 0.00

NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors. Ms. Peterson brings over 30 years of biopharmaceutical leadership experience, and currently serves on the Boards of public companies Immunocore, Inc. and Enanta...Read more


Lifeward Announces the Appointment of Mike Swinford to its Board of Directors

April 19
Last Trade: 4.89 0.00 0.00

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 19, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market lead delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, announced that the Board has approved the appointment...Read more


NeoGenomics Announces Senior Leadership Promotions

April 18
Last Trade: 14.16 0.74 5.51

FT. MYERS, Fla. / Apr 18, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately. Warren Stone has been promoted to Chief Commercial Officer and will lead NeoGenomics’ clinical and pharma services commercial teams. Stone will be responsible for sales, marketing, pharma project management, commercial...Read more


Renovaro Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient C

April 18
Last Trade: 2.02 -0.13 -6.05

LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and...Read more


Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

April 18
Last Trade: 9.61 -0.13 -1.33

Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncology’s international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets BOSTON / Apr 18, 2024 / Business Wire / Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep...Read more


Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity

April 18
Last Trade: 10.19 9.94 4,050.71

IND to be filed with the FDA in the coming weeks PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2024 / Biophytis SA (NASDAQ:BPTS) (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces the formation of a new Scientific Advisory Board to support the advancement of its phase 2 OBA clinical...Read more


Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board

April 18
Last Trade: 3.07 0.06 1.99

SAN JOSE, Calif., April 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Sanjay Juneja, MD to its Cancer Business Advisory Board. Anixa Chairman and CEO Dr. Amit Kumar stated, "Dr. Juneja is an accomplished medical oncologist who has earned status...Read more


Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care

April 18
Last Trade: 0.17 -0.01 -6.61

Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect SAN FRANCISCO, CA / ACCESSWIRE / April 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Catherine Miller...Read more


BiomX Announces the Appointment of Susan Blum to its Board of Directors

April 18
Last Trade: 0.35 0.05 17.42

CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. “We are...Read more


InMed Pharmaceuticals Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

April 18
Last Trade: 0.27 -0.0069 -2.47

Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the research, development, manufacturing, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced the addition of Dr. David G. Morgan, a renowned leader in neurodegenerative disease to its Scientific Advisory Board ("SAB") reinforcing the Company's...Read more


AdaptHealth Appoints Suzanne Foster as Chief Executive Officer

April 17
Last Trade: 9.81 0.21 2.19

PLYMOUTH MEETING, Pa. / Apr 17, 2024 / Business Wire / AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that its Board of Directors has named Suzanne Foster as its Chief Executive Officer. Ms. Foster will assume leadership of the Company from interim CEO and...Read more


89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

April 17
Last Trade: 8.92 -0.39 -4.19

SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Martin Babler to its Board of Directors, effective April 13, 2024. Mr. Babler, a highly successful executive who brings valuable industry experience to...Read more


Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

April 17
Last Trade: 11.25 0.00 0.00

Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases  BEDFORD, Mass. / Apr 17, 2024 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt...Read more


Evotec welcomes Aurélie Dalbiez as Chief People Officer

April 17
Last Trade: 7.65 0.29 3.94

HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced the appointment of Aurélie Dalbiez as the Company's new Chief People Officer ("CPO"), effective 15 June 2024. Aurélie will be joining Evotec's Management Board, bringing with her a wealth of experience and expertise in Human Resources leadership. In her role as CPO, Aurélie will oversee...Read more


Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

April 17
Last Trade: 0.72 -0.0039 -0.54

PITTSBURGH, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, today announced the expansion of its Scientific Advisory Board to include oncology expertise. The new committee members are: Jason Hafron, MD, DDS, PhD, MPH, the Chief Medical Officer at Michigan Institute of Urology, and Professor of Urology at the William Beaumont School...Read more


Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

April 16
Last Trade: 7.70 0.10 1.32

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer. Dr. Khan will lead Recursion’s research and development, and build its emerging commercial capabilities. She has also been appointed to Recursion’s Board...Read more


Ocular Therapeutix Strengthens Clinical Team with Appointment of Key Retinal Leaders

April 16
Last Trade: 5.00 -0.08 -1.57

Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed’s strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser’s vast leadership...Read more


Orthofix Medical Names Andres Cedron as New Chief Legal Officer

April 16
Last Trade: 13.22 0.14 1.07

LEWISVILLE, Texas / Apr 16, 2024 / Business Wire / Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that Andres Cedron has joined the company as Chief Legal Officer. Cedron most recently served as Vice President and Corporate Secretary at Stryker Corporation, a $20B+ global medical device company. In his corporate officer position, Cedron oversaw Stryker’s corporate governance, SEC...Read more


CareDx Appoints John W. Hanna as its New President and Chief Executive Officer

April 16
Last Trade: 8.23 0.06 0.73

BRISBANE, Calif. / Apr 16, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company’s Board of Directors, effective April 15,...Read more


Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer

April 16
Last Trade: 5.16 0.11 2.18

CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Kristian Humer will join the company as Chief Financial Officer (CFO) on April 16, 2024. Mr. Humer joins Foghorn with over 14 years of diversified financial strategy and business...Read more


Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

April 16
Last Trade: 1.37 -0.04 -2.84

ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S. Gibney has been appointed to the Company's Board of Directors, effective April 15, 2024. “We are delighted to welcome Tony to our Board of Directors as we build on our...Read more


Turnstone Biologics Appoints William Waddill to its Board of Directors

April 16
Last Trade: 3.06 0.14 4.79

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors. The Company also...Read more


BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn

April 16
Last Trade: 0.53 -0.02 -2.80

Bob Dagher, MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors   NEW YORK, April 16, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer. In addition,...Read more


Viatris Appoints Corinne Le Goff as Chief Commercial Officer

April 15
Last Trade: 11.36 0.11 0.98

PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and pharmaceutical executive with more than 25 years of experience leading and building highly successful teams...Read more


Exact Sciences Names Aaron Bloomer as New Chief Financial Officer

April 15
Last Trade: 63.53 1.12 1.79

MADISON, Wis. / Apr 15, 2024 / Business Wire / Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. He previously held leadership positions at Baxter International and 3M, where he helped improve...Read more


Envista Announces CEO Appointment

April 15
Last Trade: 20.22 0.11 0.55

BREA, Calif., April 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) announced today the appointment of Paul Keel as Chief Executive Officer and a member of the Board of Directors effective May 1, 2024. He succeeds Amir Aghdaei, who will continue to support the transition as a senior advisor. "Paul's strong track record as CEO of a public, diversified, global innovation company makes him the right leader for Envista at...Read more


CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors

April 15
Last Trade: 19.00 -0.03 -0.16

SAN MATEO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced it has appointed Kapil Dhingra, M.B.B.S., to the Company’s Board of Directors. Dr. Dhingra is a medical oncologist and a physician-scientist bringing more than 25 years of strategic...Read more


Ocular Therapeutix Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

April 15
Last Trade: 5.00 -0.08 -1.57

BEDFORD, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that Executive Chairman, Pravin U. Dugel, MD,...Read more


Shah Capital nominates two highly qualified independent director candidates for Novavax

April 15
Last Trade: 4.19 0.12 2.95

Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price       Shah Capital which owns 6.7% of Novavax, in a letter to the board says that the low share price reflects the board and management’s failure to capitalize on Novavax’s many significant competitive advantages and TAM opportunities The letter...Read more


Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer

April 15
Last Trade: 4.46 0.05 1.02

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer, replacing Adam Hansard, effective immediately. Mr. Hooks joins Applied with over 30 years of biopharmaceutical...Read more


IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

April 15
Last Trade: 1.47 0.03 2.08

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company’s lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Ms. Shamsaei joins...Read more


Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

April 15
Last Trade: 2.04 -0.05 -2.39

BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 years of drug development experience and a proven track record leading cross-functional...Read more


AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs

April 15
Last Trade: 0.43 0.0055 1.31

OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen (rintatolimod) as a potential treatment for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID. Dr. Lapp has played a key role in AIM’s long-standing AMP-511 Expanded Access Program for the treatment of...Read more


Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

April 15
Last Trade: 0.38 0.0086 2.32

Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug conjugates and platform innovation BRIDGEWATER, NJ / ACCESSWIRE / April 15, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology announced today the formation of a new...Read more


Invivyd Announces CEO Transition

April 12
Last Trade: 2.27 0.08 3.65

WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that the company’s Board of Directors has appointed Jeremy Gowler as Interim Chief Executive Officer (CEO), effective immediately, while the Board institutes a search for a permanent CEO. Mr. Gowler succeeds Dave Hering. “The Invivyd...Read more


Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

April 11
Last Trade: 3.73 0.24 6.88

MIAMI / Apr 11, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. “We are excited to add Dr. Ronaghi to complement our excellent group of current board members,” stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. “Mostafa has valuable experience in translating...Read more


Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer

April 11
Last Trade: 10.48 -0.12 -1.13

Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer Mont-Saint-Guibert, Belgium – April 11, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Dr. Maurits S. Boon, MD as Chief Medical...Read more


Black Diamond Therapeutics Announces Changes to Board of Directors

April 11
Last Trade: 5.01 -0.01 -0.20

CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancers, today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company’s Board of Directors. The Company also announced that Wendy Dixon, Ph.D., and Alex...Read more


Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

April 11
Last Trade: 2.90 0.04 1.22

REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s Strategic Advisory Board (SAB). Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications. Her deep biotechnology experience...Read more


DaVita Announces Dennis Pullin to its Board of Directors

April 10
Last Trade: 133.91 1.39 1.05

DENVER, April 10, 2024 /PRNewswire/ -- DaVita Inc. today announced that its Board of Directors has appointed a new independent director, Dennis Pullin, to join the Board, effective April 10, 2024. "We're pleased to welcome Dennis to DaVita's board," said Pamela Arway, independent chair of the DaVita Inc. Board of Directors. "Given his depth of experience within the healthcare system, we're excited about the...Read more


Henry Schein Announces Appointment of Three New Members to the Company’s Executive Management Committee

April 10
Last Trade: 72.76 0.72 1.00

Joining Henry Schein’s EMC are Steve Boggan and Bianka Wilson, Co-CEOs of the Global Oral Reconstruction Group, and Tom Popeck, CEO of the Healthcare Specialties Group MELVILLE, N.Y. / Apr 10, 2024 / Business Wire / Henry Schein, Inc. (NASDAQ: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, today announced that it has appointed three new members to the Company’s Executive...Read more


Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

April 10
Last Trade: 21.29 0.42 2.01

ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of David Nassif, J.D., as Chief Financial Officer, effective April 15, 2024. In this role, he will be responsible for refining and implementing Pharvaris’ corporate financial...Read more


Arcutis Biotherapeutics Appoints David Topper as Chief Financial Officer

April 10
Last Trade: 8.74 -0.21 -2.35

WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper has been appointed Chief Financial Officer (CFO) effective April 10, 2024. He is replacing John Smither, who rejoined Arcutis as interim CFO in August 2023. Mr. Smither will remain at Arcutis through...Read more


Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development

April 10
Last Trade: 11.97 0.02 0.17

Following significant strides made in advancing its late-stage pipeline with dual positive readouts in 2023 and a few more anticipated this year, Oculis further expands its executive leadership team with the appointment of industry veteran as President of Research & Development Dr. Shah’s joins Oculis from Iveric Bio with extensive experience in drug development, regulatory affairs and ophthalmology, with over a dozen successful...Read more


Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

April 10
Last Trade: 4.69 -0.13 -2.70

FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024. “We are excited to welcome Melita to the Terns...Read more


Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

April 9
Last Trade: 124.46 4.21 3.50

Joydeep Goswami to serve as advisor through June 30 Illumina reaffirms Q1 2024 and full-year 2024 financial guidance SAN DIEGO, April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team...Read more


Xencor Appoints Bart Cornelissen as Chief Financial Officer

April 9
Last Trade: 18.37 0.16 0.88

PASADENA, Calif. / Apr 09, 2024 / Business Wire / Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before...Read more


Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

April 9
Last Trade: 17.37 -0.25 -1.42

BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development...Read more


Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

April 9
Last Trade: 9.64 -0.16 -1.63

BOSTON / Apr 09, 2024 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience. “It is a pleasure to welcome Sunil to our Board of...Read more


enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

April 9
Last Trade: 5.50 0.59 12.02

Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve® PMA application seeking FDA approval for the VenoValve on track to be filed in Q4 of 2024 IRVINE, CA / ACCESSWIRE / April 9, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today...Read more


Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus Therapeutics’ Management Team

April 9
Last Trade: 1.63 -0.03 -1.81

The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus’ scientific and clinical efforts to develop targeted radiotherapeutics for central nervous system (CNS) cancers Dr. Blouw is an expert in CNS tumor biology and in the diagnosis of neoplasms of the cerebrospinal fluid AUSTIN, Texas, April 09,...Read more


TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

April 8
Last Trade: 7.26 0.14 1.97

WALTHAM, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer. Dr. Louis has extensive experience in hematology and oncology drug development,...Read more


Opthea Appoints John Han, PharmD, as VP Medical Affairs

April 8
Last Trade: 3.36 -0.02 -0.59

MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of John Han, PharmD, to the role of Vice President, Medical Affairs, effective April 9,...Read more


Zura Bio Announces Robert Lisicki as CEO and Director

April 8
Last Trade: 3.48 0.17 5.14

Succeeds Founding CEO, Dr. Someit Sidhu, who will continue as a Board Director Recognized as inspirational industry leader with exceptional R&D, commercial and global executive experience Outstanding product development and commercialization track record across a number of leading I&I therapies spanning nearly 30 years HENDERSON, Nev. / Apr 08, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a...Read more


TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

April 8
Last Trade: 4.47 -0.10 -2.19

MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy. Dr. Langstein is the former Chief of Plastic and Reconstructive Surgery at the University of Rochester Medical Center, known for his...Read more


Jordan McInerney Appointed as Chief Development Officer of The Oncology Institute

April 8
Last Trade: 1.18 0.05 4.42

CERRITOS, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) is pleased to announce the appointment of Jordan McInerney as the new Chief Development Officer (CDO), effective April 1, 2024. In this role, Mr. McInerney will spearhead growth initiatives for The Oncology Institute across diverse markets, including cultivating new partnerships with payors, driving M&A processes for...Read more


Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

April 8
Last Trade: 3.39 0.22 6.94

BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024. “We are thrilled to welcome Gene as our new CFO,” commented Gain CEO...Read more


Premier Health Announces the Appointment of Bruno Morel as its New CTO

April 8
Last Trade: 0.49 0.00 0.00

MONTRÉAL, April 08, 2024 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian Health tech company, announces the appointment of Bruno Morel as the Corporation’s new Chief Technology Officer, effective immediately. “We are very excited to have Bruno join Premier Health. His hiring follows our recent Canadian expansion and is one of the key catalysts of our technology...Read more


XORTX Therapeutics Welcomes New Member to the Board of Directors

April 8
Last Trade: 2.94 -0.06 -2.00

CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to...Read more


Teladoc Health Board of Directors Announces Leadership Transition

April 5
Last Trade: 13.74 0.44 3.31

Jason Gorevic to depart the company, effective immediately CFO Mala Murthy appointed acting chief executive Teladoc Health reaffirms guidance PURCHASE, NY, April 05, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today announced that Jason Gorevic is departing the company, effective immediately. The Board of Directors has appointed Mala Murthy acting Chief Executive...Read more


Sanara MedTech Announces Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer

April 5
Last Trade: 32.60 -0.30 -0.91

FORT WORTH, TX, April 05, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the appointments of Jake...Read more


IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

April 5
Last Trade: 1.47 0.03 2.08

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company’s chief business officer. Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business...Read more


Theratechnologies Appoints Elina Tea to Board of Directors

April 5
Last Trade: 1.38 0.04 2.99

MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Elina Tea, Chief Financial Officer at GLS North America, to its Board of Directors and as a member of the Company’s Audit Committee. Ms. Tea will be Investissement Québec’s...Read more


Acadia Healthcare Appoints Dr. Stephanie Eken as Chief Medical Officer

April 4
Last Trade: 70.74 0.48 0.68

FRANKLIN, Tenn. / Apr 04, 2024 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the appointment of Dr. Stephanie Eken as the Company’s new chief medical officer. Dr. Eken is a psychiatrist with more than two decades of experience across the spectrum of behavioral health. “Acadia is thrilled to welcome Dr. Eken as our new chief medical officer,” said Chris Hunter, Chief Executive Officer of Acadia Healthcare....Read more


Stevanato appoints Ugo Gay as Chief Operations Officer

April 4
Last Trade: 27.22 0.68 2.56

Strengthening corporate leadership aims to drive operational efficiencies and standardization of global processes. PIOMBINO DESE, Italy / Apr 04, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer...Read more


NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

April 4
Last Trade: 1.53 -0.08 -4.97

BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will...Read more


Co-Diagnostics Appoints New President and Other C-Level Positions

April 4
Last Trade: 1.15 0.00 0.00

SALT LAKE CITY, April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO),...Read more


Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™

April 3
Last Trade: 69.89 1.36 1.98

Pharmaceutical executive Scott Plesha named CEO Lead product ZELSUVMI expected to be commercially available in late 2024 JUPITER, Fla. & DURHAM, N.C. / Apr 03, 2024 / Business Wire / Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer. Pelthos is...Read more


Aveanna Healthcare Announces Appointment of Chief Legal Officer and Secretary

April 3
Last Trade: 2.27 0.00 0.00

ATLANTA, April 03, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced the appointment of Jerry Perchik to serve as Chief Legal Officer and Secretary, effective April 29, 2024. “I am pleased to announce the appointment of Jerry to the Chief Legal Officer and Secretary role. Jerry...Read more


Opthea Appoints Sujal Shah to the Board of Directors

April 3
Last Trade: 3.36 -0.02 -0.59

MELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Sujal Shah to the Company’s Board of Directors (the “Board”), effective April 4,...Read more


Sig Kirk Joins Assertio Board of Directors

April 3
Last Trade: 0.91 0.04 5.11

LAKE FOREST, Ill., April 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced effectiveness of the appointment of Sigurd (Sig) Kirk to its board of directors. He will serve on the Audit and Compensation committees. Kirk is a senior corporate business development...Read more


Acadia Pharmaceuticals Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

April 2
Last Trade: 16.74 -0.25 -1.47

SAN DIEGO / Apr 02, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at Acadia and serve as a member of the company’s Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia. “Liz is a preeminent drug research and...Read more


Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives

April 2
Last Trade: 37.11 -0.82 -2.16

IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S. Sales and Dr. Andrew Niekamp as Vice President of Medical Affairs. Mr. Benner will be responsible for developing effective strategies across the company's multi-product sales platform and leading a high-performance commercial team to drive therapy penetration. Dr....Read more


EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

April 2
Last Trade: 17.56 0.61 3.60

Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board  Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O, F.A.R.V.O join in advance of global Phase 3 clinical trials for EYP-1901(DURAVYU) in wet AMD  Company on track to initiate the first Phase 3 pivotal trial (LUGANO) for DURYVU in wet AMD in 2H 2024  WATERTOWN, Mass., April 02,...Read more


Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

April 2
Last Trade: 7.50 0.10 1.35

REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company’s Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as...Read more


Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

April 2
Last Trade: 2.85 -0.09 -3.06

Margaret Garin, MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn., April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced...Read more


Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International

April 2
Last Trade: 0.17 -0.01 -6.61

Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S. Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN for crofelemer in Turkey and 8 neighboring countries that entails a $2.0 million investment in Jaguar stock at a premium price SAN FRANCISCO, CA / ACCESSWIRE / April 2, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced...Read more


OneMedNet Announces CEO Succession Plan

April 2
Last Trade: 0.60 -0.01 -1.82

President, Aaron Green, Assumes Role of Chief Executive Officer  CEO, Paul Casey, Announces Retirement and Shift to Active Advisory Role to Guide Transition Successfully  Casey to Remain on Board Post-Transition  MINNEAPOLIS, April 02, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), the leading curator of regulatory-grade imaging Real World Data (“iRWD™”), today announced that its President, Aaron...Read more


Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

April 2
Last Trade: 13.00 0.79 6.47

Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors Board of Director appointments in conjunction with Avalo’s recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced the addition of multiple biotech...Read more


Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

April 2
Last Trade: 1.63 -0.005 -0.31

HOUSTON, TEXAS, April 02, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the appointment of former Acting General Counsel to the Department of Veterans Affairs, William (“Bill”) A. Hudson, Jr., to the Company’s Military & Government Advisory Board (“Advisory Board”). Nexalin’s Advisory Board provides strategic advice and counsel to support the Company’s advancement...Read more


Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

April 2
Last Trade: 6.55 0.00 0.00

BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced the appointment of Adrian Kimber as Chief Commercial Officer. Mr. Kimber joins Fractyl with over two decades of experience in the biotechnology and medical devices sectors. Throughout his...Read more


Zoetis Appoints Gavin D.K. Hattersley to its Board of Directors

April 1
Last Trade: 149.59 4.05 2.78

Molson Coors’ President and Chief Executive Officer brings valuable business leadership and global public company experience to Zoetis Board PARSIPPANY, N.J. / Apr 01, 2024 / Business Wire / Zoetis Inc. (NYSE: ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors. Mr. Hattersley brings global public company leadership...Read more


Elanco Animal Health Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors

April 1
Last Trade: 13.46 0.53 4.10

New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members. Ms. Turner...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB